image
Healthcare - Biotechnology - NASDAQ - US
$ 1.28
12.6 %
$ 147 M
Market Cap
-0.76
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one FATE stock under the worst case scenario is HIDDEN Compared to the current market price of 1.28 USD, Fate Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one FATE stock under the base case scenario is HIDDEN Compared to the current market price of 1.28 USD, Fate Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one FATE stock under the best case scenario is HIDDEN Compared to the current market price of 1.28 USD, Fate Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart FATE

image
$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0$0.5$0.5Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
13.6 M REVENUE
-78.55%
-210 M OPERATING INCOME
-10.37%
-186 M NET INCOME
-15.74%
-123 M OPERATING CASH FLOW
7.10%
12.2 M INVESTING CASH FLOW
-89.16%
99.9 M FINANCING CASH FLOW
117420.00%
1.86 M REVENUE
-39.49%
-61.7 M OPERATING INCOME
-17.89%
-52.2 M NET INCOME
-9.39%
-27.8 M OPERATING CASH FLOW
5.51%
22.8 M INVESTING CASH FLOW
-10.39%
3.13 M FINANCING CASH FLOW
0.00%
Balance Sheet Fate Therapeutics, Inc.
image
Current Assets 292 M
Cash & Short-Term Investments 279 M
Receivables 3.54 M
Other Current Assets 9.3 M
Non-Current Assets 149 M
Long-Term Investments 27.7 M
PP&E 111 M
Other Non-Current Assets 10.2 M
63.32 %6.28 %25.16 %Total Assets$440.7m
Current Liabilities 38.5 M
Accounts Payable 9.36 M
Short-Term Debt 7.42 M
Other Current Liabilities 21.7 M
Non-Current Liabilities 83.4 M
Long-Term Debt 77.8 M
Other Non-Current Liabilities 5.6 M
7.68 %6.08 %17.83 %63.83 %4.59 %Total Liabilities$122.0m
EFFICIENCY
Earnings Waterfall Fate Therapeutics, Inc.
image
Revenue 13.6 M
Cost Of Revenue 0
Gross Profit 13.6 M
Operating Expenses 224 M
Operating Income -210 M
Other Expenses -24 M
Net Income -186 M
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)14m014m(224m)(210m)24m(186m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-1542.63% OPERATING MARGIN
-1542.63%
-1366.46% NET MARGIN
-1366.46%
-58.44% ROE
-58.44%
-42.27% ROA
-42.27%
-51.34% ROIC
-51.34%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Fate Therapeutics, Inc.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -186 M
Depreciation & Amortization 9.88 M
Capital Expenditures -730 K
Stock-Based Compensation 41.5 M
Change in Working Capital 0
Others 12 M
Free Cash Flow -124 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Fate Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for FATE of $5.38 , with forecasts ranging from a low of $3 to a high of $9 .
FATE Lowest Price Target Wall Street Target
3 USD 134.38%
FATE Average Price Target Wall Street Target
5.38 USD 319.92%
FATE Highest Price Target Wall Street Target
9 USD 603.12%
Price
Max Price Target
Min Price Target
Average Price Target
99887766554433221100Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Fate Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
605 K USD 4
6-9 MONTHS
2.68 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
669 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag The FDA bestows a Regenerative Medicine Advanced Therapy tag on FATE's pipeline candidate, FT819, for treating moderate-to-severe systemic lupus erythematosus. zacks.com - 2 weeks ago
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) –   Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue with FDA throughout the development process globenewswire.com - 2 weeks ago
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on April 1, 2025 the Company granted restricted stock units (RSUs) representing 32,200 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date. globenewswire.com - 1 month ago
FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus FATE Therapeutics' Q4 loss and revenues improve year over year. Its innovative pipeline is in focus. zacks.com - 1 month ago
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates Fate Therapeutics (FATE) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.45 per share a year ago. zacks.com - 1 month ago
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe SLE globenewswire.com - 1 month ago
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on March 3, 2025 the Company granted restricted stock units (RSUs) representing 24,000 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date. globenewswire.com - 1 month ago
Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 months ago
Fate Therapeutics to Present at Upcoming Investor Conferences SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences: globenewswire.com - 2 months ago
Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies that could help oncology and immunology patients. Their pipeline has 3 interesting Phase 1 candidates for SLE, Solid Tumors, and B-cell lymphoma. But in my view, FT819 shows the most promising, as they recently achieved remission for one SLE patient. seekingalpha.com - 2 months ago
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on February 3, 2025 the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 35,000 shares of the Company's common stock at an exercise price per share of $1.27, which was the closing price per share of the Company's common stock as reported by NASDAQ on February 3, 2025, the options grant date, and (ii) restricted stock units (RSUs) representing 20,400 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% vesting in approximately equal monthly installments over the following thirty-six months, subject to the employee being continuously employed by the Company through each vesting date. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date. globenewswire.com - 2 months ago
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on January 2, 2025 the Company granted (i) non-qualified stock options to two newly-hired non-executive employees to purchase a total of 72,000 shares of the Company's common stock at an exercise price per share of $1.79, which was the closing price per share of the Company's common stock as reported by NASDAQ on January 2, 2025, the options grant date, and (ii) restricted stock units (RSUs) representing 3,200 shares of its common stock to one newly-hired non-executive employee. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% vesting in approximately equal monthly installments over the following thirty-six months, subject to the employees being continuously employed by the Company through each vesting date. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date. globenewswire.com - 3 months ago
8. Profile Summary

Fate Therapeutics, Inc. FATE

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 147 M
Dividend Yield 0.00%
Description Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Contact 12278 Scripps Summit Drive, San Diego, CA, 92131 https://www.fatetherapeutics.com
IPO Date Oct. 1, 2013
Employees 181
Officers Dr. Tunde Babalola Senior Vice President of Technical Operations Dr. Yu Cai Head of Intellectual Property & Assistant General Counsel Mr. Victor Hong Vice President of Corporate Development & Finance Ms. Jessica Francis Vice President Of Human Resources & Operations Ms. Cindy R. Tahl J.D. Chief Legal & Compliance Officer and Corporate Secretary Mr. Andrew Henry Senior Vice President of Clinical Operations